JP Morgan Chase
NUTX

JP Morgan Chase’s Nutex Health NUTX Stock Holding History

JP Morgan Chase’s Portfolio NUTX Stock Details NUTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.86M Buy
20,451
+4,318
+27% +$530K ﹤0.01% 4158
2025
Q4 		$2.66M Buy
16,133
+1,351
+9% +$179K ﹤0.01% 3865
2025
Q3 		$1.53M Buy
14,782
+6,476
+78% +$635K ﹤0.01% 4282
2025
Q2 		$1.03M Buy
8,306
+8,286
+41,430% +$1.07M ﹤0.01% 4351
2025
Q1 		$941 Hold
20
– – ﹤0.01% 6636
2024
Q4 		$634 Sell
20
-7
-26% -$199 ﹤0.01% 6783
2024
Q3 		$586 Sell
27
-492
-95% -$7.09K ﹤0.01% 6786
2024
Q2 		$3.08K Buy
519
+5
+1% +$36 ﹤0.01% 6461
2024
Q1 		$7.4K Buy
514
+427
+491% +$8.59K ﹤0.01% 6383
2023
Q4 		$2.35K Buy
87
+54
+164% +$1.68K ﹤0.01% 6698
2023
Q3 		$998 Buy
33
+2
+6% +$96 ﹤0.01% 6645
2023
Q2 		$1.95K Sell
31
-1,293
-98% -$111K ﹤0.01% 6342
2023
Q1 		$201K Buy
1,324
+102
+8% +$20.7K ﹤0.01% 5061
2022
Q4 		$348K Buy
1,222
+997
+443% +$191K ﹤0.01% 4733
2022
Q3 		$50K Buy
225
+1
+0.4% +$424 ﹤0.01% 5550
2022
Q2 		$109K Buy
+224
New +$264K ﹤0.01% 5364

Other funds holding NUTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.37B AUM 36.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WC
Winmill & Co Rochester, New York $347M AUM 37.48% 1-Year Est. Return

JP Morgan Chase's NUTX Position: Q1 2026 in Review

JP Morgan Chase increased its Nutex Health (NUTX) stake by 27% in Q1 2026, buying an estimated $530K and bringing the position to 20,451 shares worth $1.86M. The position accounts for ﹤0.01% of the portfolio, ranked #4158.

JP Morgan Chase first reported a position in NUTX in Q2 2022 and has held it in 16 quarters since. The position peaked at $2.66M in Q4 2025. 129 funds tracked by Wall St. Rank hold NUTX as of Q1 2026.

  • JP Morgan Chase held 20,451 shares of Nutex Health worth $1.86M as of Q1 2026.
  • JP Morgan Chase bought 4,318 Nutex Health shares in Q1 2026, an estimated $530K.
  • Nutex Health made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4158 holding.
  • JP Morgan Chase first reported a position in Nutex Health in Q2 2022 and has held it in 16 quarters since.
  • JP Morgan Chase's Nutex Health position peaked at $2.66M in Q4 2025.
  • 129 funds tracked by Wall St. Rank held Nutex Health as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.